by Michael C. Heinrich, MD; Arun Singh, MD; and Jonathan C. Trent, MD, PhD
For patients with gastrointestinal stromal tumors (GIST) who are receiving targeted therapy, proactive side effect mitigation strategies can greatl......READ MORE
by Michael C. Heinrich, MD; Arun Singh, MD; and Jonathan C. Trent, MD, PhD
Novel therapies are being developed and clinically tested to overcome the mechanisms of resistance after treatment with the US Food and Drug Admini......READ MORE
Patients with advanced and metastatic gastrointestinal stromal tumors (GIST) vary in their symptom burden. The treatment of the GIST itself helps t......READ MORE
patient care perspectives by Michael C. Heinrich, MD
The risk of recurrence, growth, and spread of gastrointestinal stromal tumors (GIST) after surgery relates to key variables such as the size, locat......READ MORE
Educational efforts and counseling by physicians and support staff can help to manage patient expectations and provide emotional support to newly d......READ MORE
The recent US Food and Drug Administration (FDA) approvals of 2 novel tyrosine kinase inhibitors (TKIs), avapritinib and ripretinib, may help to ov......READ MORE
